[HTML][HTML] Failure of calcineurin inhibitor (tacrolimus) weaning randomized trial in long-term stable kidney transplant recipients
E Dugast, JP Soulillou, Y Foucher, E Papuchon… - American Journal of …, 2016 - Elsevier
Long-term renal transplant outcome is limited by side effects of immunosuppressive drugs,
particularly calcineurin inhibitor (CNI). We assumed that some patients selected for a “low
immunological risk of rejection” could be eligible and benefit from a CNI weaning strategy.
We designed a prospective, randomized, multicenter, double-blind placebo-controlled
clinical study (Eudract: 2010-019574-33) to analyze the benefit–risk ratio of tacrolimus
weaning on highly selected patients (≥ 4 years of transplantation, normal histology, stable …
particularly calcineurin inhibitor (CNI). We assumed that some patients selected for a “low
immunological risk of rejection” could be eligible and benefit from a CNI weaning strategy.
We designed a prospective, randomized, multicenter, double-blind placebo-controlled
clinical study (Eudract: 2010-019574-33) to analyze the benefit–risk ratio of tacrolimus
weaning on highly selected patients (≥ 4 years of transplantation, normal histology, stable …
以上显示的是最相近的搜索结果。 查看全部搜索结果